27043 Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

Abstract

Objective: In VOYAGE-1, guselkumab(GUS) was evaluated in moderate-to-severe plaque psoriasis. In Year-1, greater proportions of GUS-treated patients vs adalimumab(ADA) achieved optimal patient-reported outcomes(PRO) of being symptom- and sign-free as well as demonstrating normal HRQoL. Here, in a post hoc analysis, we present PROs for GUS-treated patients for up to 5-years.